阿斯利康Datroway在美国获批用于治疗非小细胞肺癌

格隆汇
24 Jun

阿斯利康与日本第一三共合作研发药物Datroway获美国监管当局批准,用于曾接受治疗的非小细胞肺癌晚期病人,为该类疗法首次获美国批准使用治疗肺癌。阿斯利康将向第一三共支付4500万美元里程碑款项。Datroway针对不同类型癌症肿瘤细胞表面的TROP2蛋白,目前已获批用于治疗一种乳腺癌。该药属于抗体药物偶联物(ADC)药物,专为靶向癌细胞设计,同时避开健康细胞。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10